Redefining Parkinson's disease: microglia and systemic immunity as gateways to early therapy.
Redefining Parkinson's disease: microglia and systemic immunity as gateways to early therapy.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Luxembourg, LU · Author affiliation
Neuro-Immunology Group, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.Location evidence
Esch-sur-Alzette, LU · Author affiliation
Molecular and Functional Neurobiology Group, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.Location evidence
Lübeck, DE · Author affiliation
Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.Location evidence
A plain-language reading has not been prepared for this paper yet.